Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer.

about

Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis.

P2860

Q51075784-B5C87004-8FF7-427B-804B-885533508E5E

P2860

Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer.

Item

http://www.wikidata.org/entity/Q53786874

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Phase II trial of weekly Docet ...... ion-resistant prostate cancer.

@en

Phase II trial of weekly Docet ...... ion-resistant prostate cancer.

@nl

type

Item

label

Phase II trial of weekly Docet ...... ion-resistant prostate cancer.

@en

Phase II trial of weekly Docet ...... ion-resistant prostate cancer.

@nl

prefLabel

Phase II trial of weekly Docet ...... ion-resistant prostate cancer.

@en

Phase II trial of weekly Docet ...... ion-resistant prostate cancer.

@nl

P1476

Phase II trial of weekly Docet ...... ion-resistant prostate cancer.

@en

P2093

Elie El Rassy

http://www.w3.org/2001/XMLSchema#string

Fadi Farhat

http://www.w3.org/2001/XMLSchema#string

Joseph Kattan

http://www.w3.org/2001/XMLSchema#string

Marwan Bachour

http://www.w3.org/2001/XMLSchema#string

Marwan Ghosn

http://www.w3.org/2001/XMLSchema#string

Tarek Assi

http://www.w3.org/2001/XMLSchema#string

P2860

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis

The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.

Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC).

Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers.

Practical aspects of weekly docetaxel administration schedules.

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

Development of an oncological-multidimensional prognostic index (Onco-MPI) for mortality prediction in older cancer patients.

P2888

s10637-016-0357-4

P304

474-480

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-016-0357-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27159981

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer.

about

P2860

P2860

Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921